IRVINE, Calif., Nov. 29, 2010 /PRNewswire-FirstCall/ --
Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive
treatments for aortic disorders, announced today that John McDermott, President and Chief Executive
Officer, is scheduled to present at two upcoming investor
conferences. The first presentation will be at the 22nd
Annual Piper Jaffray Health Care Conference in New York.
Event:
|
22nd Annual Piper Jaffray Health
Care Conference
|
|
Date:
|
Tuesday, November 30,
2010
|
|
Time:
|
10:00 a.m. ET / 7:00 a.m.
PT
|
|
|
|
The second presentation will be at the 5th Annual Canaccord
Genuity Cardiovascular, Diabetes & Obesity Conference in
San Francisco.
Event:
|
5th Annual Canaccord Genuity
Cardiovascular, Diabetes & Obesity Conference
|
|
Date:
|
Tuesday, December 7,
2010
|
|
Time:
|
1:00 p.m. ET / 10:00 a.m.
PT
|
|
|
|
An audio Web cast of the Company's presentations will be
available by visiting the investor relations section of Endologix's
Web site at www.endologix.com. A replay of the presentations
will be available for 30 days.
About Endologix, Inc.
Endologix, Inc. develops and manufactures minimally invasive
treatments for aortic disorders. The Company's flagship product is
the Powerlink® System, which is an endovascular stent graft for the
treatment of abdominal aortic aneurysms (AAA). AAA is a weakening
of the wall of the aorta, the largest artery in the body, resulting
in a balloon-like enlargement. Once AAA develops, it continues to
enlarge and, if left untreated, becomes increasingly susceptible to
rupture. The overall patient mortality rate for ruptured AAA is
approximately 75%, making it a leading cause of death in the U.S.
Additional information can be found on Endologix's Web site at
www.endologix.com.
|
|
|
|
|
COMPANY
CONTACT:
|
INVESTOR
CONTACTS:
|
|
Endologix, Inc.
|
The Ruth Group
|
|
John McDermott, CEO
|
Nick Laudico (646)
536-7030
|
|
(949) 595-7200
|
Zack Kubow (646)
536-7020
|
|
www.endologix.com
|
|
|
|
|
|
|
SOURCE Endologix, Inc.